Literature DB >> 12864722

Digoxin in heart failure and cardiac arrhythmias.

Terence J Campbell1, Peter S MacDonald.   

Abstract

HEART FAILURE: Digoxin therapy has no effect on mortality in heart failure. Digoxin may be useful for maintaining clinical stability and exercise capacity in patients with symptomatic heart failure. Digoxin appears to be of most benefit in patients with severe heart failure, cardiomegaly and a third heart sound. Digoxin should be used as a second-line drug after diuretics, angiotensin-converting enzyme inhibitors and beta-blockers in patients with congestive heart failure who are in sinus rhythm. Digoxin should be used as a first-line drug in patients with congestive heart failure who are in atrial fibrillation. ARRHYTHMIAS: Digoxin has a limited, but useful, role, either alone or in combination with other agents such as beta-blockers, diltiazem or verapamil, in achieving satisfactory resting ventricular rate control in patients with chronic atrial fibrillation. In patients who lead a predominantly sedentary lifestyle (perhaps particularly in those who are elderly), digoxin alone may be the agent of choice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12864722     DOI: 10.5694/j.1326-5377.2003.tb05445.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  15 in total

1.  Suppression of Adenovirus Replication by Cardiotonic Steroids.

Authors:  Filomena Grosso; Peter Stoilov; Clifford Lingwood; Martha Brown; Alan Cochrane
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

2.  Comparative Therapeutic Potential of Cardioactive Glycosides in Doxorubicin Model of Heart Failure.

Authors:  Raquel da Silva Ferreira; Paula Bretas Ullmann Fernandes; Jéssica Pereira Oliveira da Cruz; Françoise Louanne Araújo Silva; Marthin Raboch Lempek; Gioavanni Naves Canta; Júlio César Cambraia Veado; Matheus Matioli Mantovani; Ana Flávia Machado Botelho; Marília Martins Melo
Journal:  Cardiovasc Toxicol       Date:  2021-10-16       Impact factor: 3.231

3.  Stability of Compounded Digoxin Solution 0.05 mg/mL for Injection.

Authors:  Mihaela Friciu; Ruth Bernine Marcelin; Pascal Bédard; Jean-Marc Forest; Grégoire Leclair
Journal:  Hosp Pharm       Date:  2021-07-08

4.  21-Benzylidene digoxin decreases proliferation by inhibiting the EGFR/ERK signaling pathway and induces apoptosis in HeLa cells.

Authors:  Marco Túlio C Pessôa; Jéssica M M Valadares; Sayonarah C Rocha; Simone C Silva; Jeff P McDermott; Gladis Sánchez; Fernando P Varotti; Cristóforo Scavone; Rosy I M A Ribeiro; José A F P Villar; Gustavo Blanco; Leandro A Barbosa
Journal:  Steroids       Date:  2019-12-06       Impact factor: 2.668

5.  Comparison between ivabradine and low-dose digoxin in the therapy of diastolic heart failure with preserved left ventricular systolic function.

Authors:  Giuseppe Cocco; Paul Jerie
Journal:  Clin Pract       Date:  2013-11-04

6.  Digoxin suppresses HIV-1 replication by altering viral RNA processing.

Authors:  Raymond W Wong; Ahalya Balachandran; Mario A Ostrowski; Alan Cochrane
Journal:  PLoS Pathog       Date:  2013-03-28       Impact factor: 6.823

7.  Effect of an herbal extract Number Ten (NT) on body weight in rats.

Authors:  David A York; Sonyja Thomas; Frank L Greenway; Zhijun Liu; Jennifer C Rood
Journal:  Chin Med       Date:  2007-09-14       Impact factor: 5.455

8.  A novel approach for the prediction of species-specific biotransformation of xenobiotic/drug molecules by the human gut microbiota.

Authors:  Ashok K Sharma; Shubham K Jaiswal; Nikhil Chaudhary; Vineet K Sharma
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

9.  The predictive utility of the plant phylogeny in identifying sources of cardiovascular drugs.

Authors:  Emily Guzman; Jeanmaire Molina
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

Review 10.  Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias.

Authors:  Alexandra Njegic; Claire Wilson; Elizabeth J Cartwright
Journal:  Front Physiol       Date:  2020-09-04       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.